MiNK Therapeutics, Inc. (INKT)
Develops off-the-shelf immune cells engineered to fight cancer and autoimmune diseases
$10.59-0.06%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-28.1%
The outlook
INKT is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, reflecting a bearish near-term trend. Analysts have set an average price target significantly above the current price, though coverage appears limited. The overall analyst lean is cautious relative to the stock's recent price action.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Price targetAvg target +268% vs current price
Analyst price target
~12-month · 2 analysts$39.00average target+268.3% vs now
Now $10.59
Low $35.00High $43.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$52.8M
52-wk high
$19.61
52-wk low
$8.48
50-day avg
$11.41
200-day avg
$11.78
Trailing P/E
—